ICML 2017 | The latest data in diffuse large B-cell lymphoma from ICML 2017

Andrew Davies

Andrew Davies, MD, BSc, MRCP, PhD from the University of Southampton, Southampton, UK reviews his highlights from the International Conference on Malignant Lymphoma (ICML) 2017, Lugano, Switzerland. Dr Davies comments that a lot of new data were presented during ICML 2017 including results from the REMoDL-B trial (NCT01324596), which he presented. REMoDL-B looked at improving progression-free survival by the addition of bortezomib to R-CHOP-based chemotherapy in patients with diffuse large B-cell lymphoma. This study also performed real-time gene expression profiling, and could thereby stratify patients and identify genetic links to their treatment outcomes. Dr Davies continues to discuss other interesting presentations given on many aspects of primary mediastinal large b-cell lymphoma diagnosis and treatment. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video